<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">Reumatol Clin</span><span class="iso-abbrev" title="iso-abbrev">Reumatol Clin</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Reumatologia Clinica</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1699-258X</span><span class="issn-epub" tagx="issn" title="issn-epub">1885-1398</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología.</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7298486">7298486</a></span><span class="publisher-id" title="publisher-id">S1699-258X(20)30142-X</span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1016/j.reuma.2020.06.003">10.1016/j.reuma.2020.06.003</a></span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Article</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab</div><span class="trans-title-group" tagx="trans-title-group" title="trans-title-group"><span class="trans-title" tagx="trans-title" title="trans-title">Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab</span></span></div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Figuero-Pérez</span><span class="given-names" tagx="given-names" title="given-names">Luis</span></span><span class="email" tagx="email" title="email">figuero44@gmail.com</span><a href="#aff0005">a</a><a href="#aff0010">b</a><a href="#fn0005">◊</a><a href="#cor0005">⁎</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Olivares-Hernández</span><span class="given-names" tagx="given-names" title="given-names">Alejandro</span></span><a href="#aff0005">a</a><a href="#aff0010">b</a><a href="#fn0005">◊</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Escala-Cornejo</span><span class="given-names" tagx="given-names" title="given-names">Roberto A.</span></span><a href="#aff0010">b</a><a href="#aff0015">c</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Terán-Brage</span><span class="given-names" tagx="given-names" title="given-names">Eduardo</span></span><a href="#aff0005">a</a><a href="#aff0010">b</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">López-Gutiérrez</span><span class="given-names" tagx="given-names" title="given-names">Álvaro</span></span><a href="#aff0005">a</a><a href="#aff0010">b</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cruz-Hernández</span><span class="given-names" tagx="given-names" title="given-names">Juan J.</span></span><a href="#aff0005">a</a><a href="#aff0010">b</a></span><span class="citation_author_institution" id="aff0005">[a], </span><span class="citation_author_institution" id="aff0010">[b], </span><span class="citation_author_institution" id="aff0015">[c], </span></div> <div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">⁎</span>Autor para correspondencia. <span class="email" tagx="email" title="email">figuero44@gmail.com</span></div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label">◊</span><p id="npar0005">LF-P y AO-H han contribuido de manera equitativa.</p> </div> </div><span class="pub-date-pmc-release" title="pub-date-pmc-release">pmc-release: <span>2020-6-6</span></span><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-6-6</span></span><span class="history" title="history"><span class="received" title="received">received: 2020-4-28</span><span class="accepted" title="accepted">accepted: 2020-6-10</span></span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</span></span></div> <div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Resumen</div> <p>El virus SARS-CoV-2 es un nuevo virus RNA causante de la enfermedad COVID-19, declarada como pandemia por la Organización Mundial de la Salud (OMS). Produce un cuadro de neumonía atípica que puede desembocar en un fallo multiorgánico. La desregulación del sistema inmune secundaria a la infección produce un cuadro similar al síndrome de linfohistiocitosis hemofagocítica (SLHH). Varios estudios han definido la importancia que los inhibidores de la IL-6 (tocilizumab) tienen en el tratamiento de la infección por SARS-CoV-2, sin embargo, la indicación de tratamiento con inhibidores de IL-1 (anakinra) no se encuentra establecida de forma clara.</p> <p>Presentamos el caso de un paciente de 51 años con neumonía bilateral secundaria a infección por SARS-CoV-2 refractaria al tratamiento antiviral y anti-IL-6 que presentó mejoría clínica y analítica tras el tratamiento con anti-IL-1 (anakinra).</p> </div><span class="trans-abstract" tagx="trans-abstract" title="trans-abstract"> <p>SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory response, and simulate haemophagocytic lymphohistiocytosis. Several studies have proposed that anti-IL-6 receptor antibodies, such as tocilizumab, play an important role in the treatment of severe acute respiratory infection associated with SARS-CoV-2. However, the role of anti-IL-1 receptor antibodies, such as anakinra, in the treatment of COVID-19 has not been established.</p> <p>We present a case report of a 51-year-old man diagnosed with severe respiratory infection associated with SARS-CoV-2 that was refractory to antiviral and anti-IL-6 treatment, with a favourable clinical outcome and analytical improvement after treatment with anti-IL-1 (anakinra).</p></span><div class="kwd-group"> <div class="title" tagx="title" title="title">
Palabras clave</div> <div class="kwd" title="kwd">
Anakinra</div> <div class="kwd" title="kwd">
SARS-CoV-2</div> <div class="kwd" title="kwd">
Tormenta de citocinas</div> <div class="kwd" title="kwd">
Tocilizumab</div> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Anakinra</div> <div class="kwd" title="kwd">
SARS-CoV-2</div> <div class="kwd" title="kwd">
Cytokine storm</div> <div class="kwd" title="kwd">
Tocilizumab</div> </div> </div> </div> <div class="body" title="body"> <div class="introducción" title="sec"> <div class="title" tagx="title" title="title">
Introducción</div> <p id="par0005">El virus SARS-CoV-2 es un nuevo virus RNA que fue identificado por primera vez en diciembre de 2019 en la ciudad de Wuhan, China<a href="#bib0040"><sup>1</sup></a>. SARS-CoV-2 produce un cuadro de neumonía atípica que puede desembocar en un fallo multiorgánico<a href="#bib0045"><sup>2</sup></a>. La desregulación del sistema inmune secundaria a la infección produce un cuadro similar al síndrome de linfohistiocitosis hemofagocítica (SLHH)<a href="#bib0050"><sup>3</sup></a>. Las diferentes vías de activación inmune culminan en una disfunción citotóxica cuyo principal desencadenante es una «tormenta de citocinas». Varios estudios han definido la importancia que los inhibidores de la IL-6 (tocilizumab) tienen en el tratamiento de la infección por SARS-CoV-2<a href="#bib0055"><sup>4</sup></a>. Sin embargo, la indicación de tratamiento con inhibidores de IL-1 (anakinra) no se encuentra establecida de forma clara.</p> <p id="par0010">Presentamos el caso de un paciente de 51 años con neumonía bilateral secundaria a infección por SARS-CoV-2 refractaria al tratamiento con tocilizumab que presentó mejoría tras el tratamiento con anakinra.</p> </div> <div class="casoclínico" title="sec"> <div class="title" tagx="title" title="title">
Caso clínico</div> <p id="par0015">Varón de 51 años que acudió a urgencias por cuadro de fiebre (&amp;gt; 38 °C) y disnea de una semana de evolución. El paciente presentaba antecedentes de EPOC, cirrosis hepática de origen no filiado y adenocarcinoma de recto (pT4N1M0). En el examen físico destacaba la presencia de hipoventilación generalizada con crepitantes finos bibasales. En la radiografía de tórax (<a href="#fig0005">fig. 1</a> ) se objetivaron infiltrados bilaterales con patrón en vidrio deslustrado. La analítica de sangre mostraba los valores descritos en la <a href="#tbl0005">tabla 1</a> . Los cultivos de sangre y orina fueron negativos. Se realizó detección de virus SARS-CoV-2 por reacción en cadena de polimerasa en exudado faríngeo, que fue positiva. </p><div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figura 1</span></a></div>   <p>Radiografía de tórax al ingreso donde se objetivan infiltrados alveolares bilaterales con patrón en vidrio deslustrado.</p>   </div> <div class="table-wrap_UNKNOWN" position="float" id="tbl0005"><span class="label" tagx="label" title="label">Tabla 1</span> <p>Valores analíticos del paciente durante el ingreso hospitalario</p>  <div tag="alt-text">
Tabla 1</div> <table frame="hsides" rules="groups"> <thead> <tr> <th align="left">Valores analíticos</th> <th align="left">Valores al ingreso</th> <th align="left">Valores al inicio de anakinra</th> <th align="left">Tras 48 h de inicio de anakinra</th> <th align="left">Valores al alta</th> <th align="left">Rango de valores</th> </tr> </thead> <tbody> <tr> <td align="left">Leucocitos (/μL)</td> <td align="left">9,81</td> <td align="left">4,42</td> <td align="left">8,11</td> <td align="left">6,81</td> <td align="left">(4,50-10,80)</td> </tr> <tr> <td align="left">Linfocitos (/μL)</td> <td align="left">0,71</td> <td align="left">0,87</td> <td align="left">5,60</td> <td align="left">1,28</td> <td align="left">(1,20-6,50)</td> </tr> <tr> <td align="left">Fibrinógeno (mg/dL)</td> <td align="left">720</td> <td align="left">-</td> <td align="left">436</td> <td align="left">248</td> <td align="left">(130-400)</td> </tr> <tr> <td align="left">Dímero-D (μg/mL)</td> <td align="left">0,8</td> <td align="left">1,9</td> <td align="left">1,3</td> <td align="left">1,1</td> <td align="left">(0,0-0,5)</td> </tr> <tr> <td align="left">Ferritina (ng/mL)</td> <td align="left">477</td> <td align="left">406</td> <td align="left">322</td> <td align="left">502</td> <td align="left">(30-400)</td> </tr> <tr> <td align="left">Proteína C reactiva (mg/dL)</td> <td align="left">19,68</td> <td align="left">10,01</td> <td align="left">1,60</td> <td align="left">≤ 0,1</td> <td align="left">(0,00-0,50)</td> </tr> <tr> <td align="left">Procalcitonina (ng/mL)</td> <td align="left">0,42</td> <td align="left">0,23</td> <td align="left">-</td> <td align="left">-</td> <td align="left">(0,00-0,50)</td> </tr> <tr> <td align="left">IL-6 (pg/mL)</td> <td align="left">-</td> <td align="left">&amp;gt; 1.000</td> <td align="left">-</td> <td align="left">-</td> <td align="left">(0,00-3,40)</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>-: no disponible.</p> </div> </div> </div> <p /> <p id="par0020">Ante el diagnóstico de neumonía bilateral secundaria a infección por SARS-CoV-2 se procedió al ingreso hospitalario del paciente y se inició tratamiento con antibioterapia de amplio espectro (ceftriaxona, azitromicina y posteriormente escalada a piperacilina-tazobactam), hidroxicloroquina (HCQ) y lopinavir/ritonavir (LPV/r). Ante la necesidad de soporte respiratorio se inició tratamiento con tocilizumab (8 mg/kg cada 12 h, 2 dosis subcutáneas). Dada la ausencia de mejoría respiratoria y analítica (<a href="#tbl0005">tabla 1</a>) transcurridas 48 h de la administración de tocilizumab, se decidió la administración de anakinra (100 mg dosis total única, subcutánea). Posteriormente el paciente experimentó buena evolución clínica, pudiendo retirar el soporte ventilatorio y recibiendo el alta hospitalaria a los 14 días del ingreso.</p> </div> <div class="discusión" title="sec"> <div class="title" tagx="title" title="title">
Discusión</div> <p id="par0025">La «tormenta de citocinas» secundaria a la infección por SARS-CoV-2 condiciona cuadros graves de enfermedad COVID-19. La activación desmesurada del sistema inmune produce un cuadro similar al SLHH<a href="#bib0050"><sup>3</sup></a>. El uso de anticuerpos anti-IL-6 en el tratamiento de la infección por SARS-CoV-2 se encuentra actualmente en estudio, siendo uno de los pilares actuales del tratamiento de la enfermedad COVID-19. En el estudio de Le et al<i>.</i><a href="#bib0060"><sup>5</sup></a>, tocilizumab demostró respuesta clínica tras una o dos dosis de fármaco en el 69% de los pacientes con síndrome de activación de citocinas. El uso de moléculas inhibidoras de otras interleucinas se encuentra actualmente en estudio, siendo anakinra la molécula antiinterleucina más estudiada actualmente tras el tocilizumab en el tratamiento de COVID-19<a href="#bib0065"><sup>6</sup></a>.</p> <p id="par0030">En el caso de nuestro paciente, el tratamiento con tocilizumab no aportó mejoría clínica o analítica, mientras que el uso de anakinra permitió obtener una clara mejoría en 48 h. Aunque no se puede descartar un posible beneficio debido al efecto tardío del tocilizumab. Si bien la dosis de anakinra administrada a nuestro paciente fue única, existen estudios como el de Monteagudo et al<i>.,</i> que muestran la eficacia de este fármaco en infusión continua a dosis mayores de 2.400 mg/día para el tratamiento del síndrome de activación macrofágica (SAM)<a href="#bib0070"><sup>7</sup></a>.</p> <p id="par0035">En conclusión, el bloqueo de la IL-1 de forma específica podría ser una alternativa eficaz en el manejo de pacientes con infección por SARS-CoV-2 que no se hayan beneficiado de otros tratamientos.</p> </div> <div class="conflictodeintereses" title="sec"> <div class="title" tagx="title" title="title">
Conflicto de intereses</div> <p id="par0040">LF-P: Ninguno que declarar.</p> <p id="par0045">AO-H: Ninguno que declarar.</p> <p id="par0050">RAE-C: Ninguno que declarar.</p> <p id="par0055">ET-B: Ninguno que declarar.</p> <p id="par0060">AL-G: Ninguno que declarar.</p> <p id="par0065">JJC-H: Consulting or Advisory Role: MSD Oncology, Bristol-Myers Squibb, Merck Speakers’ Bureau: MSD Oncology, Bristol-Myers Squibb, Merck, Roche, Janssen Oncology, AstraZeneca Travel, Accommodations, Expenses: MSD Oncology.</p> </div> </div> <div class="back" title="back"> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
Bibliografía</div> <li tag="ref"><a name="bib0040" /><span class="label" tagx="label" title="label">1</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lai</span><span class="given-names" tagx="given-names" title="given-names">C.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shih</span><span class="given-names" tagx="given-names" title="given-names">T.P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ko</span><span class="given-names" tagx="given-names" title="given-names">W.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tang</span><span class="given-names" tagx="given-names" title="given-names">H.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hsueh</span><span class="given-names" tagx="given-names" title="given-names">P.R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges</span><span class="source" tagx="source" title="source">Int J Antimicrob Agents.</span><span class="volume" tagx="volume" title="volume">55</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">105924</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32081636">32081636</a></span></span></li> <li tag="ref"><a name="bib0045" /><span class="label" tagx="label" title="label">2</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liang</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guan</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xe</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cancer patients in SARS-Cov-2 infection: a nationwide analysis in China</span><span class="source" tagx="source" title="source">Lancet Oncol.</span><span class="volume" tagx="volume" title="volume">21</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">335</span><span class="lpage" tagx="lpage" title="lpage">337</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S1470-2045(20)30096-6">10.1016/S1470-2045(20)30096-6</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32066541">32066541</a></span></span></li> <li tag="ref"><a name="bib0050" /><span class="label" tagx="label" title="label">3</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wampler Muskardin</span><span class="given-names" tagx="given-names" title="given-names">T.L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">IV anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of COVID19</span><span class="source" tagx="source" title="source">ACR Open Rheumatol.</span><span class="volume" tagx="volume" title="volume">2</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1002/acr2.11140">10.1002/acr2.11140</a></span></span></li> <li tag="ref"><a name="bib0055" /><span class="label" tagx="label" title="label">4</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Binqing Fu</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xiaoling</span><span class="given-names" tagx="given-names" title="given-names">X.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Haiming</span><span class="given-names" tagx="given-names" title="given-names">Wei.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Why tocilizumab could be an effective treatment for severe COVID-19?</span><span class="source" tagx="source" title="source">J Transl Med.</span><span class="volume" tagx="volume" title="volume">18</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">164</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32290839">32290839</a></span></span></li> <li tag="ref"><a name="bib0060" /><span class="label" tagx="label" title="label">5</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Le</span><span class="given-names" tagx="given-names" title="given-names">R.Q.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yuan</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shord</span><span class="given-names" tagx="given-names" title="given-names">S.S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nie</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Habtemariam</span><span class="given-names" tagx="given-names" title="given-names">B.A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe of life-threatening cytokine release syndrome</span><span class="source" tagx="source" title="source">Oncologist.</span><span class="volume" tagx="volume" title="volume">23</span><span class="year" tagx="year" title="year">2018</span><span class="fpage" tagx="fpage" title="fpage">943</span><span class="lpage" tagx="lpage" title="lpage">947</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29622697">29622697</a></span></span></li> <li tag="ref"><a name="bib0065" /><span class="label" tagx="label" title="label">6</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cron</span><span class="given-names" tagx="given-names" title="given-names">R.Q.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chatham</span><span class="given-names" tagx="given-names" title="given-names">W.W.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The rheumatologist's role in COVID-19</span><span class="source" tagx="source" title="source">J Rheumatol.</span><span class="volume" tagx="volume" title="volume">47</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">639</span><span class="lpage" tagx="lpage" title="lpage">642</span><span class="pub-id"><a href="https://dx.doi.org/10.3899/jrheum.200334">10.3899/jrheum.200334</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32209661">32209661</a></span></span></li> <li tag="ref"><a name="bib0070" /><span class="label" tagx="label" title="label">7</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Monteagudo</span><span class="given-names" tagx="given-names" title="given-names">L.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Boothby</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gertner</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome</span><span class="source" tagx="source" title="source">ACR Open Rheumatol.</span><span class="volume" tagx="volume" title="volume">2</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">276</span><span class="lpage" tagx="lpage" title="lpage">282</span><span class="pub-id"><a href="https://dx.doi.org/10.1002/acr2.11135">10.1002/acr2.11135</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32267081">32267081</a></span></span></li> </ul> </div> </div>  </body></html>